2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2009
Letter by Brown and Pretorius Regarding Article, “Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients”
Brown NJ, Pretorius M. Letter by Brown and Pretorius Regarding Article, “Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients”. Circulation 2009, 120: e159; author reply e160. PMID: 19901200, DOI: 10.1161/circulationaha.109.874743.Peer-Reviewed Original Research
2002
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema
Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. Hypertension 2002, 39: 460-464. PMID: 11882590, DOI: 10.1161/hy0202.103054.Peer-Reviewed Original ResearchConceptsDPPIV activityHypertensive volunteersHypertensive subjectsRemote historyAcute ACE inhibitionSerum DPPIV activityUntreated hypertensive controlsUntreated hypertensive subjectsMetabolism of bradykininDipeptidyl peptidase IV activityAcute ACEIChronic ACEiPeptidase IV activityCorticosteroid treatmentHypertensive controlsHypertensive patientsNormotensive volunteersNormotensive controlsACE inhibitorsACE inhibitionSubstance PBradykinin degradationAssociated angioedemaACEIAngioedema
1999
Role of Angiotensin II in Coagulation and Fibrinolysis
Brown N, Vaughan D. Role of Angiotensin II in Coagulation and Fibrinolysis. Heart Failure Reviews 1999, 3: 193-198. DOI: 10.1023/a:1009757416302.Peer-Reviewed Original ResearchAntithrombotic effectAngiotensin type 1 receptor antagonistType 1 receptor antagonistVascular fibrinolytic balanceRenin-angiotensin systemTissue plasminogen activatorHypertensive patientsInhibitor PAI-1Angiotensin IIFibrinolytic balanceReceptor antagonistVasculoprotective propertiesPlatelet functionEnzyme inhibitorsPAI-1Plasminogen activatorMultiple mechanismsFibrinolysisSubstantial evidenceRecent studiesAngiotensinPatientsProstanoidsAntagonist
1997
Plasminogen actiwator inhibitor type 1 in diabetes and hypertension
Litchfield W, Brown N, Vaughan D. Plasminogen actiwator inhibitor type 1 in diabetes and hypertension. Current Opinion In Endocrinology Diabetes And Obesity 1997, 4: 233-238. DOI: 10.1097/00060793-199706000-00009.Peer-Reviewed Original ResearchCardiovascular riskPAI-1Inhibitor type 1Type 1Elevated levelsIncreased cardiovascular riskRenin-angiotensin systemEndogenous fibrinolytic systemPlasminogen activator inhibitor type 1Activator inhibitor type 1Tissue plasminogen activatorHypertensive patientsEssential hypertensionMyocardial infarctionCardiovascular diseaseFibrinolytic systemHypertensionPlasminogen activatorStrong associationIncidenceRiskPrimary inhibitorHyperinsulinemiaHypertriglyceridemiaInfarctionSelective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin
Brown N, Nadeau J, Vaughan D. Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin. Thrombosis And Haemostasis 1997, 77: 522-525. PMID: 9066005, DOI: 10.1055/s-0038-1656000.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininCaptoprilFemaleHumansHypertensionIsoquinolinesMalePlasminogen Activator Inhibitor 1QuinaprilRandomized Controlled Trials as TopicTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsT-PA antigen levelsTissue-type plasminogen activatorMean arterial pressureT-PA levelsAntigen levelsPAI-1 antigen levelsInfusion of bradykininSympathetic nervous systemEffect of bradykininTissue-type plasminogen activator secretionHypertensive patientsHemodynamic effectsArterial pressurePlasminogen activator secretionAngiotensin IIAnimal modelsPotent stimulusNervous systemPAI-1ACEIBradykininBradykinin resultsSelective stimulationPlasminogen activatorSignificant decrease
1996
Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. Journal Of Pharmacology And Experimental Therapeutics 1996, 279: 703-12. PMID: 8930174.Peer-Reviewed Original ResearchConceptsACE inhibitorsVasodepressor responseProstacyclin responsesEnzyme inhibitorsHigh-renin hypertensive patientsContribution of prostacyclinPlacebo-treated subjectsMean arterial pressureProstaglandin-independent mechanismEffect of bradykininDegradation of bradykininBradykinin doseProstacyclin metaboliteHypertensive patientsHypotensive responseVasodepressor effectArterial pressureBlood pressureACE inhibitionPGF1 alphaUrinary excretionProstacyclin productionProstaglandin productionBradykininClass effect